Afatinib (BIBW2992) in HER2-overexpressing Inflammatory Breast Cancer
Condition: Breast NeoplasmsInterventions: Drug: Afatinib once daily (OD); Drug: Vinorelbine WeeklySponsor: Boehringer IngelheimActive, not recruiting - verified October 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Inflammatory Breast Cancer | Research